Integrative analysis reveals CRHBP inhibits renal cell carcinoma progression by regulating inflammation and apoptosis.
Kang YangYusha XiaoTao XuWeimin YuYuan RuanPengcheng LuoFan ChengPublished in: Cancer gene therapy (2019)
Patients with renal cell carcinoma (RCC) usually develop drug resistance and have poor prognosis owing to its insensitive property. However, the underlying mechanisms of RCC are still unclear. We implemented an integrative analysis of The Cancer Genome Atlas and Gene Expression Omnibus datasets. Three genes (CRHBP, RAB25 and PSAT1) were found to be potential biomarkers in ccRCC and validated by four independent cohorts. Then, ccRCC patients with a decreased expression of CRHBP in tumor tissues had significantly poor survival by TCGA ccRCC datasets and verified by clinical samples as well as RCC cell lines. Overexpression of CRHBP suppressed cell proliferation, migration, invasion as well as apoptosis in vitro and in vivo. Moreover, the results of western blot analysis showed the effects of CRHBP via upregulating NF-κB and p53-mediated mitochondria apoptotic pathway. Our results suggested that CRHBP may be an effective target to treat ccRCC patients.
Keyphrases
- renal cell carcinoma
- poor prognosis
- oxidative stress
- gene expression
- cell death
- cell proliferation
- long non coding rna
- end stage renal disease
- cell cycle arrest
- endoplasmic reticulum stress
- ejection fraction
- genome wide
- pi k akt
- chronic kidney disease
- dna methylation
- newly diagnosed
- signaling pathway
- peritoneal dialysis
- prognostic factors
- rna seq
- cell migration
- single cell
- nuclear factor
- transcription factor
- network analysis
- young adults
- reactive oxygen species
- binding protein
- data analysis